|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||18.19 - 18.19|
|52-week range||17.78 - 37.70|
|Beta (5Y monthly)||-0.07|
|PE ratio (TTM)||9.05|
|Forward dividend & yield||0.50 (2.42%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
The London-listed drugmaker now expects revenue from its generics unit to be between $710 million and $750 million for 2022, with core operating margin of around 20%. The revised outlook comes in stark contrast to the company's trading statement last week, when it had forecasted revenue from the business to grow 8% to 10% over 2021 sales of $820 million and predicted core operating margin in the range of 24% to 25%. FTSE 100-listed shares of Hikma, which supplies many generic drugs including pain medications, anaesthetics and sedatives, were down 9.6% at 1,667.5 pence by 0739 GMT and were the biggest loser on the UK blue-chip index.
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.